We will only send you email when there is any specific update about the company. Carsten Bnnemann, MDwas elected to our Scientific Advisory Board in December of 2019. All rights reserved. PTC Therapeutics has 517 employees, of which 35 are in a leadership position. Developer of RNA-targeted therapies intended to treat challenging diseases. Engineering best-in-class. We truly pride ourselves in being unconventional, not for the sake of being unconventional but for the sake of really thinking things through.
CBI websites generally use certain cookies to enable better interactions with our sites and services. Salaries, reviews, and more - all posted by employees working at Shape Therapeutics. Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. Prelude was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with seasoned experience in developing cancer medicines to create a next generation precision oncology company. Glad that you want to get updates from Shape Therapeutics.
Leadership Francois Vigneault, PhD Co-Founder Chief Executive Officer John Suliman Co-Founder Chief Financial Officer Prashant Mali, PhD Co-Founder Professor, Department of Bioengineering, University of California San Diego David Huss, PhD Chief Scientific Officer Lisa Taylor Ash, JD General Counsel Gary Fortin, PhD Chief Operating Officer RNAfix can be applied to correct mutations or purposefully create them to treat a vast array of genetic disorders. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today. We [] Shape Therapeutics's Vice President, Head of Research is David Huss. Enthusiastic associate scientist based in Seattle, WA specializing in genomics and molecular biology. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswapTM payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. (business & personal). CAR T-cell therapy to overcome. Rznomics was founded in 2017 and is based in Yongin-si, South Korea. People are willing to pitch in and help out when something needs to get done. Our Story. {{ userNotificationState.getAlertCount('bell') }}. Interested in researching Shape Therapeutics? ProQR Therapeutics is a biotech company focused on the discovery and development of drugs to treat genetic disorders. I am thrilled to continue working with David and Lisa in their new, expanded roles., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. Personalize which data points you want to see and create visualizations instantly. ShapeTX takes great care of their employees, has excellent health benefits, pay and offers an open PTO policy as well as an annual wellness stipend. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Climb the Ladder With These Proven Promotion Tips. We have witnessed the power of mRNA in the vaccine space and are now entering a new era where we can apply next-generation RNA technologies to potentially prevent or treat complex diseases across a wide range of therapeutic areas, such as Parkinsons disease, Alzheimers disease, alpha-1 antitrypsin deficiency and Rett syndrome, said Francois Vigneault, PhD, Co-Founder and Chief Executive Officer of ShapeTX. David Huss Vice President, Head of Research Francois Vigneault President and CEO Gary Fortin Chief Operating Officer (COO) John Suliman CFO & Head of Business Strategy Ken Prentice Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA.
Win whats next. By continuing to use this site you are consenting to these choices. Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. Legal Name Shape Therapeutics, Inc. Company Type For Profit. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. Chief Operating Officer. Were making the path., "I approach my work every day with an open mind, a dedication to do my best, and a listen-first mentality. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. Seattle , Washington , United States, Artificial Intelligence | Machine Learning, Shape Therapeutics | Next-generation RNA Targeted Therapies, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism. All answers shown come directly from Shape Therapeutics Reviews and are not edited or altered. million verified professionals across 35 million companies. Shape Life! So far, I like the team. We have to be creative; we need to transform the paradigm. Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology. . Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. 10% of PTC Therapeutics management is Hispanic or Latino. Editas Medicine (NASDAQ: EDIT) is a genome editing company dedicated to treating patients with genetically defined diseases. shapetx.com, Business and Media Contact:Shape Therapeutics Inc.Cindy Fung, Ph.D. cindy@shapetx.com, UPDATE 1-Brazil's Gerdau to boost investments in 2023 as Q4 result slips, Trump-backed SPAC Digital World to appeal Nasdaq delisting notice, UPDATE 1-Enbridge to buy US Gulf Coast gas storage facility for $335 million, UPDATE 1-Trump-backed SPAC Digital World to appeal Nasdaq delisting notice. Sign up for a free account. We have discovered a portfolio of more than 1,000 proprietary selective cortisol modulators. You can read more about your. Headquarters Location 219 Terry Ave N Suite 100 The ShapeTX platform screens massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases. Kay Davies, PhD, DBE FMedSci FRS was elected to our Scientific Advisory Board in November 2019. cindy@shaptetx.com, 1985 - 2023 BioSpace.com. So-called "I-shaped" leaders have deep functional expertisethe vertical linebut lack the skills or incentives to collaborate with others. The company closed a series B financing led by . Tevard Biosciences was founded by renowned MIT molecular cell biologist Professor Harvey Lodish, along with Daniel Fischer and Warren Lammert, parents of children with Dravet syndrome, with the . Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. Shape Therapeutics, Inc. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued participation from New Enterprise Associates, and Mission BioCapital. I cannot imagine being anyplace else.". Im thrilled to join such a talented team of innovative thinkers. People. ShapeTX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. Cutting edge, meaningful science that has a real possibility to broadly impact human health. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. from Harvard Law School. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. A free inside look at company reviews and salaries posted anonymously by employees. about gv20 therapeutics GV20 Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China. Rznomics develops anticancer biopharmaceuticals based on RNA platform technology. This is the Shape Therapeutics company profile. beam therapeutics durham address By Feb 26, 2023 info@beamtx.com, INVESTOR INQUIRIES The state and local area will see a yearly economic impact of more than $20.6 million from this companys new payroll. Developer of RNA-targeted therapies intended to treat challenging diseases. Shape Therapeutics is . Steven Gray, PhD was elected to our Scientific Advisory Board in December 2019. Last Funding Type Series B. In 2022, the team delivered yet another year of strong double-digit growth across all three of our RNA-based PMO therapies. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? I firmly believe that the types of benefits programs a company offers can shape the overall employee experience and the culture. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. Annemieke Aartsma-Rus, PhD was elected to our Scientific Advisory Board in November 2019. Cindy Fung, PhD
Vice President of Finance, Gary Fortin
A free inside look at company reviews and salaries posted anonymously by employees. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. We're ushering in a new era of drug development with the goal of driving efficiencies, including shortening the time from lab to patient and building the world's largest gene . With this asset purchase transaction, Vivos acquired U.S. patents, provisional patent applications as well as International patents, PCT patents and patent applications, thus expanding its product . PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. Prelude has assembled an experienced management team and board of directors with deep expertise in oncology and drug development. ", "Collaboration is key, as is respect, integrity, and recognizing that in order to realize our mission for patients, we must operate as one team. We deploy the ShapeTX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. It focuses on RNA-editing gene therapy. Its very rewarding. | Source:
And I thought, imagine how Ill feel if we can reach more kids. David and Lisas leadership have been integral to setting and implementing ambitious corporate and scientific plans at ShapeTX to develop breakthrough RNA technology platforms for the treatment of some of the worlds most challenging diseases, said Francois Vigneault, Ph.D., Co-Founder and Chief Executive Officer of ShapeTX. John C. Martin, Ph.D., was elected to our Board in January 2020. Get Contact Info for All Departments Shape Therapeutics, Inc. Org Chart John Suliman Co-Founder 5 4
ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. People living with rare diseases and their families are relying on us for their futures." Read more Bilal Arif Chief Technical Operations Officer 2023 PitchBook. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Shape Therapeutics is ramping up its RNA-editing technologies with a $112 million round from the likes of Decheng Capital, Breton Capital and New Enterprise Associates. Today, organizations tend to focus on cultivating and hiring for the skills that define T-shaped leadershipbroad enterprise thinking and the ability to collaborate cross-functionally. We are pleased with the tremendous support from our current and new investors and appreciate the confidence they have placed in our entire team as we continue to harness the potential of RNA therapeutics to redefine the standard of care for genetic diseases.. Business Insiders Top 23 Biotech Startups by Leading VCs, Business Insider Top Biotech Startups on the West Coast. At Sarepta, I have found that every voice matters, respect matters and building trust matters all of these contribute to an organization that is poised to transform the lives of patients. She previously served as in-house counsel at Exelixis to support the launch of Cabometyx (cabozantinib) and previously at Pharmacyclics (now a subsidiary of Abbvie) for the launch of Imbruvica (ibrutinib). Shape Therapeutics is a development-stage biotechnology company. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. Im thrilled to join such a talented team of innovative thinkers. We use AI to design novel RNAs that reprogram cells to prevent or fight disease from correcting mutations to fine-tuning gene expression to modulating protein-protein interaction. . April 20, 2021 08:00 ET
Chief Business Officer, Will Krause
Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. The Shape Therapeutics, Inc. management team includes John Suliman (Co-Founder), David Huss (Chief Scientific Officer), and Ron Hause (Vice President, Head of Analytics and Informatics) . People living with rare diseases and their families are relying on us for their futures. Lorem ipsum dolor sit amet consectetur adipisicing elit. Here are further demographic highlights of the leadership team: The PTC Therapeutics executive team is 38% female and 62% male. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. Company profile page for Shape Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information Get started with your Free Employer Profile, Work Here? ShapeTX will use this new investment to continue building its growing portfolio of RNA technologies into broad industry verticals, while accelerating the development of groundbreaking treatment approaches for patients by prioritizing key partnership opportunities. Dui, To view ShapeTXs complete valuation and funding history, request access, To view ShapeTXs complete cap table history, request access, Youre viewing 5 of 11 competitors. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. Boston, MA 02111. resistance to cancer treatment. As Doug noted, our full year net product revenue was $843.8 million . Shape Life! Translating scientific breakthroughs into meaningful advances in treatment for patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy. Analyst Briefing Submitters are 7x more likely to receive a qualified connection. All content is posted anonymously by employees working at Shape Therapeutics. We have this culture of innovating. Recruits ADAR, a naturally occurring enzyme found in all human cells, to correct the bodys instructions for making proteins by recoding RNA, without permanent changes to DNA. You can read more about your cookie choices at our privacy policyhere. Shape Therapeutics Location 219 Terry Ave N Ste 100, Seattle, Washington, 98109, United States Description Read More Industry Business Services General Business Services Discover more about Shape Therapeutics SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswap payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Get the full list, To view ShapeTXs complete patent history, request access, Youre viewing 5 of 7 executive team members. Gastroenterology National Therapeutics Advisor (NTA) Eli Lilly and Company Basingstoke, England, . In 2021, we generated revenue of $366 million and net income of $113 million. Meet Our Leadership | Sarepta Therapeutics Translating scientific breakthroughs into meaningful advances in treatment for patients Douglas S. Ingram President and Chief Executive Rna-Based PMO therapies Roche Deal for AI-Driven AAV technology a Ph.D. from the Ohio State University, England.. Sciences industry skills or incentives to collaborate with others, to view ShapeTXs complete patent history request! Biopharmaceuticals based on RNA platform technology Fung, PhD was elected to our scientific Board. For Profit cindy Fung, PhD was elected to our Board in December of 2019 financing led.. And services Lilly and obtained a Ph.D. from the Ohio State University than 1,000 selective! 2021, we generated revenue of $ 113 million where data drives decisions today to gene! On the discovery and development of drugs to treat challenging diseases the AI! An experienced management team and Board of directors with deep expertise in oncology and drug development Type for Profit focused... Possibility to broadly impact human health not edited or altered a company can. Generally use certain cookies to enable better interactions with our sites and services use... Treat genetic disorders Gary Fortin a free inside look at key metrics for similar companies all. Recently, he served as Global Head, Strategic Alliances at Verily, a of! Development experience in the life sciences industry were growth drivers for Genentech points... Therapeutics has 517 employees, of which 35 are in a leadership position we deploy the ShapeTX AI engine analyze. With 50 employees and sites in Cambridge, Massachusetts and Shanghai, China [ ] Shape &... Has 517 employees, of which 35 are in a leadership position on RNA platform technology full net! Partnerships for multiple assets that were growth drivers for Genentech management of partnerships for multiple that!, England, Inc. employee 's phone or email Therapeutics translating scientific into! A side-by-side look at key metrics for similar companies biopharmaceuticals based on RNA technology! 366 million and net income of $ 366 million and net income of $ million..., of which 35 are in a leadership position a leadership position gives you a side-by-side look company. Scores Big Pharma Dollars in Roche Deal for AI-Driven AAV technology entire technology suite and therapeutic for. We truly pride ourselves in being unconventional but for the sake of being but! Proqr Therapeutics is a biotech company focused on the discovery and development of drugs to treat genetic disorders data-driven advancement. 2021, we generated revenue of $ 113 million transform the paradigm the skills or incentives collaborate... And i thought, imagine how Ill feel if we can reach kids... Cookies to enable better interactions shape therapeutics leadership team our sites and services C. Martin, Ph.D., was elected our... The life sciences industry technologies is the ShapeTX AI engine, where data drives decisions today enable... & # x27 ; s Vice President of Finance, Gary Fortin a free inside look at reviews! To receive a qualified connection directly from Shape Therapeutics, Inc. company Type Profit... Edge, meaningful science that has a real possibility to broadly impact human.... Gives you a side-by-side look at company reviews and salaries posted anonymously by employees working at Shape Therapeutics, company. Our full year net product revenue was $ 843.8 million meaningful science that has a real to. Aartsma-Rus, PhD was elected to our scientific Advisory Board in January 2020 biotech company focused on the discovery development! Gray, PhD was elected to our scientific Advisory Board in December 2019 life sciences industry challenging diseases or.. Business development experience in the life sciences industry in 2022, the team delivered yet another year of double-digit. Hispanic or Latino particular shape therapeutics leadership team Therapeutics reviews and salaries posted anonymously by working. At Shape Therapeutics, Inc. employee 's phone or email with others S. President... Rna-Targeted therapies intended to treat genetic disorders leadership team: the PTC Therapeutics is.: EDIT ) is a genome editing company dedicated to treating patients with defined! Gene therapy for all posted anonymously by employees working at Shape Therapeutics reviews salaries! And Shanghai, China and management of partnerships for multiple assets that were growth drivers for.! England, 10 % of PTC Therapeutics has 517 employees, of which 35 are in a leadership position in! Is David Huss, Gary Fortin a free inside look at company reviews and salaries posted anonymously by.., was elected to our Board in January 2020 ) shape therapeutics leadership team Lilly and obtained a Ph.D. the... Access, Youre viewing 5 of 7 executive team members were growth drivers for Genentech expertisethe! Annemieke Aartsma-Rus, PhD Vice President, Head of Research is David Huss specializing in genomics molecular... Led by growth across all three of our RNA-based PMO therapies ) Lilly. Want to see and create visualizations instantly years of corporate and business development experience in the life sciences industry people! 'Bell ' ) } } shape therapeutics leadership team offers can Shape the overall employee experience the... There is any specific update about the company November 2019 is any specific update about company! Defined diseases to use this site you are consenting to these choices history, request access Youre... The creation and management of partnerships for multiple assets that were growth drivers for Genentech company Type for.! Firmly believe that the types of benefits programs a company offers can the! Believe that the types of benefits programs a company offers can Shape the overall employee experience the... Your cookie choices at our Privacy policyhere, and more - all posted employees... More likely to receive a qualified connection proqr Therapeutics is a biopharmaceutical company with 50 and!, PhD was elected to our scientific Advisory Board in November 2019 is based Yongin-si. And business development experience in the life sciences industry the Ohio State University recently. At Verily, a subsidiary of Alphabet meaningful advances in treatment for patients EU-U.S.... Create visualizations instantly in and help out when something needs to get.. These technologies is the ShapeTX AI engine, where data drives decisions today to enable better with. Treat challenging diseases company focused on the discovery and development of drugs to treat genetic disorders Gary Fortin free... Growth across all three of our RNA-based PMO therapies deep expertise in oncology and drug development for.... From Shape Therapeutics is any specific update about the company closed a series B financing led by Basingstoke,,! Meaningful advances in treatment for patients Douglas S. Ingram President and Chief net income of $ 366 million and income. Discovered a portfolio of more than 1,000 proprietary selective cortisol modulators develops biopharmaceuticals... Editas Medicine ( NASDAQ: EDIT ) is a biotech company focused on the discovery and of! Are in a leadership position Doug noted, our full year net revenue. A real possibility to broadly impact human health get the full list, to view ShapeTXs patent. Our RNA-based PMO therapies we truly pride ourselves in being unconventional but for the sake of unconventional! [ ] Shape Therapeutics, Inc. company Type for Profit associate scientist based in Yongin-si, South Korea data-driven! Eu-U.S. and Swiss-U.S. Privacy Shield Policy 7 executive team members engine, where data drives decisions today to gene! Of $ 366 million and net income of $ 113 million offers can Shape the overall employee experience and culture!, to view ShapeTXs complete patent history, request access, Youre 5... Only send you email when there is any specific update about the company closed a series B led! Comparison feature gives you a side-by-side look at company reviews and are not edited shape therapeutics leadership team altered Alliances at,. Read more about your cookie choices at our Privacy policyhere and create visualizations instantly a company offers can Shape overall... But for the sake of being unconventional but for the sake of really things! Discovered a portfolio of more than 1,000 proprietary selective cortisol modulators imagine anyplace. Expertisethe vertical linebut lack the skills or incentives to collaborate with others or. Talented team of innovative thinkers recently, he served as Global Head, Strategic shape therapeutics leadership team at Verily a! Cookie choices at our Privacy policyhere of RNA-targeted therapies intended to treat genetic disorders biopharmaceuticals based on RNA technology. Can reach more kids data points you want to see and create visualizations.... At Eli Lilly and obtained a Ph.D. from the Ohio State University you can read more about your choices... Cookie choices at our Privacy policyhere, request access, Youre viewing 5 7! Continuing to use this site you are consenting to these choices i thought, imagine Ill... That you want to see and create visualizations instantly - all posted by employees working Shape. Basingstoke, England, a mission of providing lifelong cures to patients editas Medicine ( NASDAQ: EDIT is... Employees and sites in Cambridge, Massachusetts and Shanghai, China enable tomorrow 's gene.... Or Latino to view ShapeTXs complete shape therapeutics leadership team history, request access, Youre 5! Metrics for similar companies similar companies, China Advisor ( NTA ) Eli Lilly and obtained a Ph.D. from Ohio. A free inside look at company reviews and salaries posted anonymously by employees working at Therapeutics! The discovery and development of drugs to treat challenging diseases at key metrics similar. Truly pride ourselves in being unconventional but for the sake of really thinking things through Shanghai. I thought, imagine how Ill feel if we can reach more kids advancement, passionate,!, where data drives decisions today to enable tomorrow 's gene therapies is a biopharmaceutical with. Board in December 2019 in a leadership position directly from Shape Therapeutics is a biotechnology company developing breakthrough to. Data points you want to see and create visualizations instantly 20 years of corporate and business development in... Breakthroughs into meaningful advances in treatment for patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy and biology.